Transforming medicine and changing lives
April 29, 2021Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
Methylmalonic Acidemia (MMA) program to become wholly-owned by Selecta. Selecta to postpone IND submission until at least the fourth quarter of 2021. Empty capsid (SEL-399) study remains on track ...read the news
We are on a never-ending quest to advance genetic technology
and life-saving AAV gene therapy
In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is leading the way.
Work with us
Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.
Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.